跳至主要内容
临床试验/JPRN-UMIN000020206
JPRN-UMIN000020206招募中2 期

High-dose-rate brachytherapy as monotherapy for intermediate- and high-risk prostate cancer: A phase II clinical trial - Monotherapeutic HDR-BT for intermediate- and high-risk prostate cancer: Phase II

Osaka University0 个研究点目标入组 100 人开始时间: 2015年12月20日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
Male

入选标准

  • 未提供

排除标准

  • 1) Active other malignancy 2) Uncontrollable diabetes mellitus 3) Unstoppable anticoagulant drugs 4) Severe neurocognitive disease 5) Collagen disease 6) Previous surgery or irradiation to the pelvis 7) Previous TUR-P 8) Severe BPH or lower urinaly tract symptoms 9) Low-risk prosatate cancer 10) High-risk prostate cancer with all 3 factors of T3-4, GS >=, and PSA >=20 11) Neoadjucant hormone therapy >1 year 12) Castration-resistant prostate cancer 13) The physician juddged contraindication

研究者

相似试验